Mikael Dolsten is a seasoned and accomplished industry executive with extensive global pharmaceutical management experience. He most recently served as the Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, Inc., where he led global R&D strategy and portfolio advancement for more than 16 years and was instrumental in the development of breakthrough innovations spanning small molecules, biologics, gene therapies, and vaccines. His leadership has shaped portfolios at Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions exceeding $100 billion in value. He has also contributed to more than 36 drug approvals, many representing breakthroughs in the oncology field, during his tenure as leader of Pfizer global R&D-Medical. Mikael currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals and holds advisory roles with leading investment and innovation groups including Blackstone Life Sciences, GV (formerly Google Ventures), Bain & Company, and Formation Bio. He is a Visiting Professor at Lund University and a member of the Royal Swedish Academy of Engineering Sciences, and has advised U.S. and U.K. leadership on public health and pandemic preparedness. He received a Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden.